For in vitro diagnostic use. Others Elecsys Anti-SARS-CoV-2 S IVD Elecsys® Anti-SARS-CoV-2 S CPS_000616 09 289 275 190 9 289 275 190 09289275190 9289275190 09289275190 Anti-SARS-CoV-2 S Elecsys E2G 300 Elecsys Anti-SARS-CoV-2 S 07613336180679 Reagents, kits 300 tests cobas e 402/801 true 09 289 267 190 9 289 267 190 09289267190 9289267190 09289267190 Anti-SARS-CoV-2 S Elecsys cobas e 200 Elecsys Anti-SARS-CoV-2 S 07613336180662 Reagents, kits 200 tests cobas e 411/601/602 true 09289275500 Elecsys Anti-SARS-CoV-2 S en 5 FF0000000635450E FF00000004A7C40E 09289275190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of total antibodies to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2) spike (S) protein receptor binding domain (RBD) in human serum and plasma. The test is intended as an aid to assess the adaptive humoral immune response, including neutralizing antibodies, to the SARS‑CoV‑2 S protein after natural infection with SARS‑CoV‑2 or in vaccine recipients.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09289267500 Elecsys Anti-SARS-CoV-2 S en 4 FF0000000637140E FF0000000447D70E 09289267190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of total antibodies to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2) spike (S) protein receptor binding domain (RBD) in human serum and plasma. The test is intended as an aid to assess the adaptive humoral immune response, including neutralizing antibodies, to the SARS‑CoV‑2 S protein after natural infection with SARS‑CoV‑2 or in vaccine recipients.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en

User Profile

Select your user profile

Elecsys^® Anti-SARS-CoV-2 S

Overview

Detailed Specifications

Ordering Information

Compatible Instruments

Technical Documents